Verrica reports inducement grant under nasdaq listing rule 5635(c)(4)

West chester, pa., dec. 09, 2024 (globe newswire) -- verrica pharmaceuticals inc. (“verrica” or the “company”) (nasdaq: vrca), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that verrica's compensation committee granted david zawitz, verrica's new chief operating officer, a nonqualified stock option to purchase 950,000 shares of its common stock under the company's inducement plan, effective december 9, 2024. the stock option was granted as a material inducement to mr. zawitz's employment with verrica in accordance with nasdaq listing rule 5635(c)(4).
NDAQ Ratings Summary
NDAQ Quant Ranking